Latigo Biotherapeutics, Inc.: Blue Owl Capital Holdings LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Blue Owl Capital Holdings LP disclosed a stake exceeding 5% in Latigo Biotherapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001140361-26-043775). The 13G is the short-form ownership report used by passive investors, indicating Blue Owl is not seeking control of the clinical-stage biotech. The exact share count and percentage were not specified in the filing headline. The disclosure signals institutional backing for Latigo, a private-to-public-track company, and matters because large holders can influence liquidity and governance. Next, watch for an amended 13G or 13D if Blue Owl's position or intent changes, and for Latigo's own periodic reports detailing its ownership structure.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Blue Owl Capital Holdings LP, Latigo Biotherapeutics, Inc.